Targeting the lung using siRNA and antisense based oligonucleotides
Moschos, S. A., Spinks, K., Williams, A. E. and Lindsay, M. A., 2008. Targeting the lung using siRNA and antisense based oligonucleotides. Current Pharmaceutical Design, 14 (34), pp. 3620-3627.
Related documents:This repository does not currently have the full-text of this item.
You may be able to access a copy if URLs are provided below. (Contact Author)
The accessibility to topical administration through inhalation, combined with its large surface area, has led to speculation that the lung might offer an ideal target for the application of oligonucleotide based therapeutics. In this review, we shall critically examine the challenges facing antisense and siRNA based approaches for target validation in vivo and as potential therapeutics. In particular, we shall discuss the antisense and siRNA based approaches in relation to factors such as delivery, distribution, stability, off-target effects, unwanted immune responses and the selection of the optimum mRNA targets.
|Creators||Moschos, S. A., Spinks, K., Williams, A. E. and Lindsay, M. A.|
|Uncontrolled Keywords||in-vivo, antisense, mouse, induced pulmonary-fibrosis, airways, oligonucleotide, induced pneumonopathy, rna interference, antigen-induced eosinophilia, phosphorothioate, lung, sirna, airway hyperresponsiveness, gene-expression, vascular endothelium, small interfering rna, common beta-chain|
|Departments||Faculty of Science > Pharmacy & Pharmacology|
Actions (login required)